LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells
Qi Tang, Xintong Zhao, Hui Li, Jiaqian Liao, Bingyu Ouyang, Chunxiao Ma, Dedian Chen · 2025
Read LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells by Qi Tang, Xintong Zhao, Hui Li, Jiaqian Liao, Bingyu Ouyang, Chunxiao Ma, Dedian Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12738774.txt.
Description
Tang and co-authors identified a protein that helps breast cancer cells resist the drug ribociclib. The drug blocks cell-cycle enzymes and is a standard targeted treatment, but resistance commonly develops. The team compared cancer tissues and cell lines and found the nuclear envelope protein LEM4 raised in tumors, with high levels tied to worse patient survival. In lab-grown resistant cells, LEM4 was higher still.
Silencing LEM4 made resistant cells sensitive again, in dishes and in animal tumors. The mechanism runs through beta-catenin, a signaling protein: LEM4 binds it, keeps it stable, and helps it enter the nucleus and switch on genes. Blocking that signal reversed the resistance. The authors propose the LEM4 and beta-catenin link as a drug target for patients whose cancers stop responding to ribociclib.
Catalog record
| CREATOR | Qi Tang, Xintong Zhao, Hui Li, Jiaqian Liao, Bingyu Ouyang, Chunxiao Ma, Dedian Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |